The goal of a new study published in The Journal of Pediatrics was to determine whether trace amounts of ethylene glycol (EG), diethylene glycol (DEG), or triethylene glycol (TEG) in polyethylene glycol (PEG) could be implicated in increased blood levels of EG, DEG, or TEG in children receiving daily PEG therapy. In this study, blood specimens were collected from nine children between 6 and 12 years old who were being treated for constipation with PEG 3350, before and every 30 minutes for three hours after receiving 17 gms of PEG 3350. Additionally, PEG 3350, tap water, and blood samples from 18 age- and sex-matched controls were analyzed. It was found that baseline blood levels of EG and TEG were identical among the control and the treated groups. Whereas, DEG levels were lower in the PEG 3350 group. Meanwhile, after PEG 3350 dose, levels of EG and TEG peaked at 90 minutes, but DEG levels did not change considerably. Standard 17-gm doses of PEG 3350 in 237 mL of water led to concentrations of EG, DEG, and TEG of 1.32 ± 0.23 µg/mL, 0.18 ± 0.03 µg/mL, and 0.12 ± 0.01 µg/mL, respectively. While EG, DEG, and TEG levels in public water supply were 0.07 µg/mL, 0.21 µg/mL, and 0.02 µg/mL, respectively. From the results, it was concluded that daily PEG 3350 therapy in children was not associated with sustained elevation of EG, DEG, or TEG blood levels relative to those in matched controls. It was stated that despite the increased EG and TEG levels after a standard dose of PEG 3350, their peak values remained well below toxic levels in pediatric patients.